Stopped: Early discontinuation based on sponsor decision not driven by any safety concerns.
This is a first-in-human (FIH) Phase 1/Phase 2 study for evaluating SAR445514 in monotherapy in participants with relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory light chain amyloidosis (RRLCA). The study will comprise 3 parts: A dose escalation phase (Part 1) in RRMM participants (Part 1a) that will evaluate several doses administered to determine 2 doses that will be tested in the dose optimization part. A dose escalation will also be done in RRLCA participants (Part 1b) but started sequentially after the end of the dose escalation in RRMM participants. This dose escalation will evaluate the 2 doses planned to be used in dose optimization in RRMM, to ensure those doses are safe also for RRLCA participants. A dose optimization phase (Part 2) that will be evaluating 2 doses determined from Part 1 to determine the preliminary recommended Phase 2 dose (pRP2D) and schedule for SAR445514 in RRMM. A dose expansion phase (Part 3) that will evaluate the preliminary efficacy of pRP2D and schedule for SAR445514 in RRMM (Part 3a) and RRLCA (Part 3b). Approximately 111 participants will be enrolled and treated by study intervention and separated as such: Part 1a: Approximately 30 to 40 participants Part 1b: Approximately 6 to 12 participants Part 2: Approximately 30 participants Part 3a: Approximately 15 participants Part 3b: Approximately 14 participants
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Dose escalation (part 1a - RRMM) Presence of dose limiting toxicities (DLT)
Timeframe: Cycle 1 - 4 weeks per cycle
Dose escalation (part 1a - RRMM) Percentage of participants experiencing treatment-emergent adverse events (TEAEs)
Timeframe: From Baseline to end of follow-up (approx. 15 months)
Dose optimization (part 2 - RRMM) Overall response rate (ORR)
Timeframe: Cycles 1 to 4 - 4 weeks per cycle
Dose escalation (part 1b - RRLCA) Presence of dose limiting toxicities (DLT) at cycle 1
Timeframe: Cycle 1 - 4 weeks per cycle
Dose escalation (part 1b - RRLCA) Percentage of participants experiencing treatment-emergent adverse events (TEAEs)
Timeframe: From baseline to end of follow-up (approx. 15 months)
Dose expansion (part 3 - RRMM) Overall response rate (ORR)
Timeframe: Cycles 1 to 4 - 4 weeks per cycle
Dose expansion (part 3-RRLCA) Hematological response (HR)
Timeframe: Cycles 1 to 4 - 4 weeks per cycle